Full history for every metric is available with a Kvantra account
Össur hf. (OSSR.CO)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 613 | 686 | 630 | 719 | 719 | 786 | 804 |
| Operating profit | $m | 89 | 93 | |||||
| Net profit | $m | 80 | 66 | 6 | 64 | 43 | 58 | 57 |
| EPS reported | $ | 0.14 | 0.14 | |||||
| Operating cashflow per share | $ | 0.22 | 0.22 | |||||
| Capex per share | $ | 0.10 | 0.10 | |||||
| FCF per share | $ | 0.12 | 0.12 | |||||
| Free cash flow | $m | 52 | 47 | |||||
| Net debt | $m | 395 | 344 | |||||
| Book value equity | $m | 702 | 732 | |||||
| Book value per share | $ | 1.67 | 1.68 | |||||
| Number of shares | m | 420.32 | 434.74 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 29.02 | - | |||||
| P/B LTM | x | 2.43 | 2.68 | |||||
| P/S LTM | x | 2.17 | 2.44 | |||||
| P/FCF LTM | x | 32.74 | 41.91 | |||||
| EV/EBITDA LTM | x | 14.59 | 15.97 | |||||
| EV/Sales LTM | x | 2.67 | 2.87 | |||||
| Earnings Yield LTM | % | 3.45% | 3.03% | |||||
| FCF Yield | % | 3.05% | 2.39% | |||||
| Quality | ||||||||
| ROE | % | 8.32% | 8.73% | |||||
| ROIC | % | 5.61% | 5.61% | |||||
| Operating margin | % | 11.38% | 11.38% | |||||
| Gross margin | % | 61.80% | 61.80% | |||||
| FCF/Sales | % | 6.62% | 6.62% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +40.00% | +33.97% | |||||
| Sales Growth YoY | % | +9.33% | +10.21% | |||||
| Net Income Growth YoY | % | +37.34% | +30.96% | |||||
| FCF Growth | % | +49.43% | +66.18% | |||||
| Operating Profit Growth | % | +37.85% | +37.05% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.11 | 0.08 | |||||
| Net Debt/EBITDA | x | 2.75 | 2.75 | |||||
| EBIT/Net interest | x | 4.98 | 4.98 | |||||
| Net debt/market cap | % | 23.18% | 17.57% | |||||
| Net debt/Equity | x | 0.56 | 0.47 | |||||
| Gross debt/equity | x | 0.67 | 0.77 | |||||
Company overview
Össur hf. and its subsidiaries are actively involved in the creation, advancement, manufacturing, and global distribution of non-invasive orthopedic medical devices. Their reach extends across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's operations are divided into two main business units: Prosthetics and Bracing & Supports. The Prosthetics division supplies both mechanical devices, such as lower limb and finger prostheses, and cutting-edge bionic products. These bionic solutions, designed for amputees, incorporate microprocessor-controlled feet, knees, hands, liners, and other integrated components featuring sensors, computing power, intrinsic intelligence, and actuators. In contrast, the Bracing & Supports segment offers a variety of supportive equipment for areas like the spine, knees, hips, feet, ankles, and hands. These products serve both therapeutic and preventative purposes by stabilizing joints and other body parts, in addition to providing injury management solutions to aid the healing of fractures and ligament injuries. Össur's primary customer base consists of specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgical centers. The company distributes its offerings through a combination of its own direct sales force and a network of third-party distributors. Founded in 1971 and headquartered in Reykjavik, Iceland, Össur hf. operates as a subsidiary of William Demant Invest A/S.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Össur hf. (OSSR.CO)
Össur hf. and its subsidiaries are actively involved in the creation, advancement, manufacturing, and global distribution of non-invasive orthopedic medical devices. Their reach extends across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's operations are divided into two main business units: Prosthetics and Bracing & Supports. The Prosthetics division supplies both mechanical devices, such as lower limb and finger prostheses, and cutting-edge bionic products. These bionic solutions, designed for amputees, incorporate microprocessor-controlled feet, knees, hands, liners, and other integrated components featuring sensors, computing power, intrinsic intelligence, and actuators. In contrast, the Bracing & Supports segment offers a variety of supportive equipment for areas like the spine, knees, hips, feet, ankles, and hands. These products serve both therapeutic and preventative purposes by stabilizing joints and other body parts, in addition to providing injury management solutions to aid the healing of fractures and ligament injuries. Össur's primary customer base consists of specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgical centers. The company distributes its offerings through a combination of its own direct sales force and a network of third-party distributors. Founded in 1971 and headquartered in Reykjavik, Iceland, Össur hf. operates as a subsidiary of William Demant Invest A/S.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free